Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nuvation Bio Inc (NUVB)

Nuvation Bio Inc (NUVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 758,800
  • Shares Outstanding, K 218,046
  • Annual Sales, $ 0 K
  • Annual Income, $ -75,800 K
  • 60-Month Beta 1.42
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.25
Trade NUVB with:

Options Overview Details

View History
  • Implied Volatility 104.04% ( -11.50%)
  • Historical Volatility 58.47%
  • IV Percentile 44%
  • IV Rank 13.13%
  • IV High 781.85% on 10/27/23
  • IV Low 1.59% on 02/27/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 51
  • Volume Avg (30-Day) 29
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 671
  • Open Int (30-Day) 876

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.07
  • Number of Estimates 4
  • High Estimate -0.05
  • Low Estimate -0.09
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.51 +30.94%
on 04/22/24
3.55 -7.60%
on 05/15/24
+0.68 (+26.16%)
since 04/19/24
3-Month
1.67 +96.41%
on 03/25/24
4.16 -21.15%
on 03/28/24
+1.50 (+84.28%)
since 02/21/24
52-Week
0.95 +245.27%
on 11/01/23
4.16 -21.15%
on 03/28/24
+1.65 (+101.23%)
since 05/19/23

Most Recent Stories

More News
Biotech Sector Advances in Pancreatic Cancer Research

USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working...

BRX : 22.15 (-1.64%)
ONCY : 1.1200 (+0.90%)
ONC.TO : 1.51 (-2.58%)
NVS : 102.67 (-0.17%)
IBRX : 6.99 (-0.71%)
ACRS : 1.2200 (+2.52%)
NUVB : 3.28 (-5.74%)
Biotech’s Role in Addressing the Pancreatic Cancer Emergency

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END

NVX : 2.40 (-3.43%)
ONCY : 1.1200 (+0.90%)
ONC.TO : 1.51 (-2.58%)
NVS : 102.67 (-0.17%)
IBRX : 6.99 (-0.71%)
ACRS : 1.2200 (+2.52%)
NUVB : 3.28 (-5.74%)
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial...

NUVB : 3.28 (-5.74%)
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial...

NUVB : 3.28 (-5.74%)
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced it has dosed...

NUVB : 3.28 (-5.74%)
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial...

NUVB : 3.28 (-5.74%)
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial...

NUVB : 3.28 (-5.74%)
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that it...

NUVB : 3.28 (-5.74%)
Nuvation Bio Inc. (NUVB) Upgraded to Buy: What Does It Mean for the Stock?

Nuvation Bio Inc. (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NUVB : 3.28 (-5.74%)
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment...

NUVB : 3.28 (-5.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nuvation Bio Inc. is a biopharmaceutical company. It engages in developing differentiated and novel therapeutic candidates for unmet needs in oncology. Nuvation Bio Inc., formerly known as Panacea Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 3.77
2nd Resistance Point 3.63
1st Resistance Point 3.56
Last Price 3.28
1st Support Level 3.35
2nd Support Level 3.21
3rd Support Level 3.14

See More

52-Week High 4.16
Last Price 3.28
Fibonacci 61.8% 2.93
Fibonacci 50% 2.55
Fibonacci 38.2% 2.18
52-Week Low 0.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar